Episode notes
Season 4 - Episode 2
In the second episode of ILCA’s Liver Cancer Podcast, hosted by Sarah Cappuyns, MD, PhD, a Gastroenterology resident and member of the Y-ILCA Committee, we are joined by Jeroen Dekervel, Digestive Oncologist at the University Hospital in Leuven, Belgium.
In this episode, they engage in a discussion on the emerging role of biomarkers in guiding systemic therapy for hepatocellular carcinoma (HCC). They explore the need for reliable biomarkers to predict treatment response and tailor therapeutic approaches in HCC. The conversation highlights the most promising biomarkers currently being investigated, including those related to immunotherapy and targeted treatments and discusses their potential impact on the future of precision medicine in HCC management.
Keywords
liver cancerhccsystemic therapybiomarkershepatocellular carcinoma